|
|
|
|
Continuing Medical Education (CME) Activity Alert: “A Collaborative Approach to Treating Hormone Refractory Prostate Cancer”
SOURCE: CME2
12:04PM, October 26, 2005
Advanced Registration Available for this CME Breakfast Symposium
Montvale, NJ – October 25, 2005 – In conjunction with the American Urological Association Northeastern/New England Section Annual Meeting, CME2 and the Albert Einstein College of Medicine are pleased to announce that advanced registrations are now available for “A Collaborative Approach to Treating Hormone Refractory Prostate Cancer,” a CME Breakfast Symposium which will be held on Thursday, November 3, 2005, 6:45 AM to 7:50 AM at the Mid-Ocean Amphitheatre, The Fairmont Southampton, Southampton, Bermuda.
Urologists, urology residents, and other physicians treating prostate cancer are invited to participate in a series of programs and case presentations that will be led by featured faculty including Mitchell C. Benson, MD—Chair, George F. Cahill Professor and Chairman, Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, and Daniel Petrylak, MD, Associate Professor of Medicine, Division of Medical Oncology, Columbia University Medical Center, New York, NY.
Symposium participants will earn a maximum of 1 Category 1 credit toward the American Medical Association (AMA) Physician’s Recognition Award. Upon completion of this activity, participants should be able to describe the major findings of recent clinical trials in advanced prostate cancer patients, identify the diagnostic profiles of patients at all stages of the prostate cancer clinical spectrum, describe the risks and benefits of treatment options, describe ongoing clinical trials, evaluate the appropriate treatment options for patients with advanced prostate cancer diagnostic profiles, and describe how they would collaborate with oncologists to improve patient outcomes. To register for this activity, visit www.urologytimes.com.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Albert Einstein College of Medicine and CME2, an independent subsidiary of Advanstar Communications Inc. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Conflict-of-Interest Disclosure Statement
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
The Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
Special Needs
Albert Einstein College of Medicine and Montefiore Medical Center fully intend to comply with the legal requirements of the Americans with Disabilities Act. If any participant in this symposium is in need of special accommodations, please contact Heather Steelman at 203-221-4612, ext 5225, at least 1 week prior to the activity.
This educational activity is jointly sponsored by Albert Einstein College of Medicine, Montefiore Medical Center, and CME2, an independent subsidiary of Advanstar Communications, Inc, publisher of Urology Times. This activity is made possible by an unrestricted educational grant from sanofi-aventis.
For additional information visit
www.urologytimes.com/urologytimes/static/staticHtml.jsp?id=189918
|
|
|
|
|
|
